Background. Markers of inflammation are linked to malnutrition and confer an increased mortality risk in hemodialysis patients. Ultrapure dialysate might have a beneficial effect on markers of inflammation. We conducted a metaanalysis that examined the effect of ultrapure versus standard dialysate on markers of inflammation, oxidative stress, nutrition and anemia parameters. Methods. We performed a literature search using MEDLINE, Scopus, Cochrane Central Register of Controlled Trials, ClinicalTrials.gov and scientific abstracts. Single-arm studies, nonrandomized and randomized controlled trials were included. We conducted random effects model meta-analyses to assess changes in the aforementioned outcomes. Results. We identified 16 single-arm studies, 2 crossover and 3 parallel-arm nonrandomized controlled trials and 5 crossover and 5 parallel-arm randomized controlled trials.
Introduction
Inflammatory markers are elevated in patients with chronic kidney disease [1, 2] . This is particularly salient in patients with chronic kidney failure receiving long-term hemodialysis [3] whose blood comes in contact through the dialyzer with a large volume of dialysate [4, 5] . The purity of the dialysate and the permeability of the dialyzer to bacterial soluble products might contribute, in part, to some of the acute and long-term complications of dialysis, including, pyrogenic reactions, the malnutrition inflammation-atherosclerosis syndrome, dialysis-related amyloidosis, erythropoietin hyporesponsiveness and accelerated cardiovascular morbidity [6] [7] [8] [9] . Although this conceptual framework was first introduced in the 1980s, ultrapure dialysate has now become a standard for hemodialysis with the ultimate goal of improving the quality of dialysis delivery [10] [11] [12] [13] .
The Association for the Advancement of Medical Instrumentation (AAMI) standards define ultrapure dialysate according to a bacterial count of <0.1 colony-forming units (CFUs)/mL and an endotoxin level of less than 0.03 EU/mL [14] . In vitro dialysis studies demonstrate that cytokine production by peripheral blood leukocytes is influenced by levels of endotoxin contamination in the dialysate compartment and the dialyzer membrane's permeability [4] . Use of dialysate with lower endotoxin contamination is associated with lower levels of proinflammatory cytokines, C-reactive protein (CRP) and oxidative stress markers [15] [16] [17] [18] . To date, only a few studies have examined the concentration-dependent effect of bacterial contamination of the dialysate on clinical outcomes, including nutritional indices and erythropoietin requirement [17, 19] , and the relative importance of dialysate purity as a trigger of a chronic inflammatory state remains unclear. In addition, the potential clinical benefits of ultrapure dialysate are difficult to ascertain due to the confounding effects of patient-and dialysis-related factors, including the dialyzer type (e.g. use of high-flux synthetic dialyzer membranes) and the dialysis modality (e.g. use of hemodiafiltration) [20, 21] . Although European and Japanese clinical practice guidelines support the regular use of ultrapure dialysate for hemodialysis [22, 23] , this additional step is costly, limiting its widespread adoption. To systematically review the evidence, we conducted a meta-analysis of all the studies that examined the potential benefits of ultrapure versus standard dialysate on markers of inflammation, oxidative stress, nutrition and anemia parameters, and investigated sources of heterogeneity.
Materials and methods

Data sources and searches
We performed a MEDLINE literature search (inception-April 2012) to identify eligible studies using the search terms 'ultrapure dialysate', 'ultrapure dialysis fluid', 'ultrapure dialysis solution', 'ultrapure hemodialysis solution', 'dialysate purity', or 'dialysate quality' (Supplementary Table S1 ). The search was limited to human studies. We also searched Scopus, and the Cochrane Central Register of Controlled Trials and Clin-icalTrials.gov for completed studies using similar search terms, and reviewed the American Society of Nephrology abstracts (2003-2011 meetings), as well as the bibliographies of retrieved articles.
Study selection
We included single-arm studies (with pre-and poststudy evaluations), and crossover as well as parallel-arm nonrandomized and randomized controlled trials of patients on long-term hemodialysis examining the effect of ultrapure versus standard dialysate on markers of inflammation, oxidative stress, nutrition and anemia parameters, including erythropoietin dose. Studies of hemofiltration and hemodiafiltration were excluded to minimize the confounding effect of convective clearance on the markers of interest. The inflammatory markers of interest were circulating levels of bacterial endotoxin, CRP, interleukin-6 (IL-6), interleukin-1 receptor antagonist (IL-1Ra), tumor necrosis factor-α (TNF-α) and β2-microglobulin. Markers of oxidative stress included circulating levels of pentosidine, myeloperoxidase and oxidized low density lipoprotein (LDL) cholesterol. Other outcomes of interest were serum albumin, a nutritional marker and anemia parameters, including hemoglobin, ferritin, transferrin saturation and erythropoietin or darbepoetin dose. There were no restrictions on language, sample size or duration of follow-up. Two of the authors (P.S. and C.R.) independently screened the titles and abstracts of all electronic citations. The full-text articles were retrieved for comprehensive review and were independently rescreened.
Data extraction and quality assessment
The following data were extracted: country of origin, year of publication, study design, sample size, percentage of men, mean age, mean duration of dialysis and prevalence of diabetes. Characteristics of the dialysis treatment were also extracted, including dialyzer type (high versus low flux), dialyzer reuse versus single-use practices and definition of ultrapure dialysate. If reported in units/kg/week, the weekly total erythropoietin dose was converted to units/week by using the mean weight of patients in each study arm. If not reported, a mean weight was imputed using the study country-specific mean weight derived from the Dialysis Outcomes and Practice Patterns Study [24] . When reported, the darbepoetin-α dose was converted to an equivalent erythropoietin-α dose using a dose conversion ratio of 331 units of erythropoietin-α per 1-μg of darbepoetin-α [25, 26] . Where indicated, the G3 data graph analyzer (version 1.5.3) was used to extract data from graphs. The data were extracted by two of the authors (P.S. and C.R.). Disagreements were resolved through consensus and arbitration by a third author (B.L.J.). The quality of the single-arm studies and experimental study arms was assessed using the Newcastle-Ottawa Scale [27] . This scale assesses the quality of observational studies and allocates a maximum of 9 stars (or points) for quality of selection (up to 4 points), comparability (up to 2 points) and outcome (up to 3 points) of study participants. Overall study quality was defined arbitrarily as poor (score, 0-3), fair (score, [4] [5] [6] or good (score, 7-9). The Jadad score was used to assess the quality of the randomized controlled trials [28] .
Data synthesis and analysis
Using the data derived from single-arm studies and experimental study arms of crossover and parallel-arm controlled trials, we first conducted random effects model meta-analyses [29] to examine the effect of ultrapure dialysate on changes in serum markers of inflammation and oxidative stress, serum albumin and anemia parameters. For the nonrandomized and randomized (crossover and parallel-arm) controlled trials, we performed random effects model meta-analyses to assess net changes in the same outcome variables.
Existence of heterogeneity among effect sizes of individual studies was assessed using the I 2 index and Q statistic. The I 2 index describes the percentage of total variation across studies, which is due to true heterogeneity rather than chance, with a value ≥50% indicating moderateto-high heterogeneity [30] . Investigations of heterogeneity were based on the following selected study characteristics: dialyzer type (high versus low flux), dialyzer reprocessing practices (reuse versus single use), study duration (≤6, 7-12 and >12 months) and study quality. Random effects model meta-regression analyses were also performed to examine the relationship of the mean dialysis duration (in years) to the mean change in the outcomes of interest. Funnel plots and the Egger test were used to assess publication bias [31] . The meta-analyses were performed using Comprehensive Meta-Analysis version 2.0 (Biostat, www.meta-analysis. com), and Open_Meta (http://tuftscaes.org/open_meta/download.html). Figures for the subgroup analyses were generated using the R system software version 2.13.0 (cran.rproject.org/bin/windows/base/old/2.13.0).
Results
Study characteristics
A total of 918 potentially relevant citations were identified and screened; 181 articles were retrieved for detailed evaluation, of which 31 fulfilled eligibility criteria ( Figure 1 ) [8, 9, 15-17, 19, 32-56] , representing 16 single-arm (cohort) studies, 2 crossover and 3 parallel-arm nonrandomized controlled trials, and 5 crossover and 5 parallel-arm randomized controlled trials. Characteristics of the individual studies are displayed in Table 1 . The studies spanned >20 years and varied in sample size (6-342 patients). Mean age ranged from 47 to 72 years, duration of dialysis from 0.9 to 11.8 years and prevalence of diabetes from 0 to 78%. Single-arm studies were considered of fair (score of 4-6) to good (score of 7-9) quality, and the randomized controlled trials, of fair (score of 2-3) quality.
Effect of ultrapure dialysate on markers of inflammation and oxidative stress
In an analysis of 23 study arms reporting on CRP, by meta-analysis, the baseline mean CRP level was 8.63 mg/ L (95% CI 6.62, 10.64). Conversion from standard to ultrapure dialysate resulted in a significant decrease in mean CRP level of 3.19 mg/L (95% CI −4.62, −1.75; P < 0.001; Table 2 ). In an analysis of nine controlled trials, a larger net decrease in CRP level was observed (−4.38 mg/L; 95% CI −7.47, −1.29; P = 0.006; Table 3 ).
In an analysis of 16 study arms reporting on IL-6 and 2 study arms reporting on oxidized LDL cholesterol, ultrapure dialysate resulted in a significant decrease in mean IL-6 level of 5.43 pg/mL (95% CI −8.38, −2.48; P < 0.001), and in mean oxidized LDL cholesterol level of 6.90 U/L (95% CI −12.88, −0.93; P = 0.024) ( Table 2 ). In an analysis of nine controlled trials reporting on IL-6 and two controlled trials reporting on oxidized LDL cholesterol, a larger net decrease in mean IL-6 (−11.61 pg/mL; 95% CI −17.74, −5.49; P < 0.001) and mean oxidized LDL cholesterol (−14.04 U/L; 95% CI −21.26, −6.83; P < 0.001) was observed ( Table 3) .
In an analysis of seven study arms reporting on IL-1Ra and eight study arms reporting on TNF-α, ultrapure dialysate resulted in a significant decrease in mean IL-1Ra level of 0.16 ng/mL (95% CI −0.26, −0.06; P = 0.002), and in mean TNF-α level of 13.29 pg/mL (95% CI −22.06, −4.51; P = 0.003) ( Table 2 ). However, in an analysis of the two controlled trials reporting on IL-Ra and the three controlled trials reporting on TNF-α, smaller nonsignificant net decreases in mean IL-1Ra and TNF-α levels were observed ( Table 3 ).
The effect of ultrapure dialysate on other circulating markers of inflammation and oxidative stress, including changes in levels of bacterial endotoxin, β2-microglobulin, pentosidine and myeloperoxidase are summarized in Table 2 , demonstrating a significant decrease in all these markers with the exception of plasma endotoxin. There was moderate-to-high heterogeneity among effect sizes, as evidenced by the I 2 index (≥50%) and Q-statistic Pvalue, in most of the analyses, with the exception of those examining changes in levels of pentosidine, myeloperoxidase and oxidized LDL cholesterol ( Table 2) .
Effect of ultrapure dialysate on nutritional markers
In an analysis of 14 study arms reporting on serum albumin, by meta-analysis, the baseline mean serum albumin level was 3.85 g/dL (95% CI 3.75, 3.94). Conversion from standard to ultrapure dialysate resulted in a significant increase in serum albumin of 0.11 g/dL (95% CI 0.02, 0.19; P = 0.011). A larger net increase in mean serum albumin of 0.25 g/dL (95% CI 0.02, 0.48; P = 0.031) was observed in the four controlled trials.
Effect of ultrapure dialysate on anemia parameters
In an analysis of 11 study arms reporting on hemoglobin, by meta-analysis, the baseline mean hemoglobin level was 10.60 g/dL (95% CI 10.07, 11.13). Conversion from standard to ultrapure dialysate resulted in a significant increase in mean hemoglobin level of 0.40 g/dL (95% CI 0.06, 0.75; P = 0.022). In an analysis of five controlled trials, a smaller net increase in mean hemoglobin level of 0.13 g/dL (95% CI 0.00, 0.26; P = 0.049) was observed ( Table 3) .
In an analysis of seven study arms reporting on ferritin, and four study arms reporting on transferrin saturation, ultrapure dialysate did not result in a significant change in serum ferritin level or transferrin saturation rate ( Table 2) .
The effects of ultrapure dialysate on erythropoietin requirement are summarized in Tables 2 and 3 . In an experimental study arms, stratified by dialyzer type, dialyzer reprocessing, study duration and study quality. In brief, use of ultrapure dialysate resulted in a significant decrease in mean CRP level in studies that used high-flux dialyzers, single-use dialyzers or unspecified reuse practices, and in those of ≤12-month duration (Figure 2A) . Similarly, use of ultrapure dialysate resulted in a significant decrease in mean IL-6 level in studies that used highflux dialyzers, single-use dialyzers, unspecified dialyzer reuse practices and in those of ≤6-month duration ( Figure 2B ). Use of ultrapure dialysate resulted in a significant increase in mean serum albumin in studies that did not specify the dialyzer type and in those of 7-to 12month duration ( Figure 2C ). Finally, ultrapure dialysate resulted in a significant decrease in the mean weekly erythropoietin dose in patients ( Figure 2D ). Supplementary Figure S1 displays the results of the same subgroup analyses in controlled trials. In brief, use of ultrapure dialysate resulted in a significant net decrease in mean CRP and IL-6 level and erythropoietin dose in studies that used high-flux or single-use dialyzers, with a variable impact of study duration on these parameters. There was also a significant net increase in mean serum albumin levels in studies that used similar dialyzer characteristics.
Investigations of heterogeneity
By meta-regression analysis, longer duration of dialysis (in years) was associated with a smaller mean change in albumin level, but a larger mean change in TNF-α and hemoglobin level (Supplementary Figure S2) .
Funnel plots for the key outcomes were symmetric (data not shown), and the Egger test was not significant, suggesting less susceptibility to publication bias (Tables 2  and 3) , with the exception of IL-6, TNF-α and hemoglobin, in which the funnel plots were asymmetric.
Discussion
In the present meta-analysis, we demonstrate that the use of ultrapure dialysate in patients with chronic kidney failure on long-term hemodialysis is associated with a significant decrease in several markers of inflammation, including CRP and IL-6, two nontraditional cardiovascular risk markers in the dialysis population [1, [57] [58] [59] . There was also a significant improvement in serum albumin, a dual marker of nutrition and inflammation (as a negative acute-phase reactant) and a potent predictor of adverse clinical outcomes [60, 61] , and an improvement in several anemia parameters, with an increase in hemoglobin level coupled to a decrease in the weekly erythropoietin dose. These observations remained significant in analyses of cohort studies and nonrandomized as well as randomized controlled trials, and across several subgroup analyses investigating sources of heterogeneity.
Worldwide, hemodialysis is the most commonly used treatment modality for patients with chronic kidney failure. Despite technological advances in the delivery of hemodialysis and standardization of the therapy through the widespread adoption of clinical practice guidelines [62] , the annual mortality rate of patients with kidney failure on long-term hemodialysis remains alarmingly high, with cardiovascular disease remaining the leading cause of death [63] . A malnutrition-inflammation-atherosclerosis syndrome has been postulated to play a role in the pathogenesis of accelerated cardiovascular disease in the dialysis population [64] . Proinflammatory cytokines such as TNF-α and IL-6 are likely important contributors to the accelerated cardiovascular disease that is observed in dialysis patients [65] , and trigger an acute-phase reaction by the liver, resulting in an increase in CRP levels and a decrease in serum albumin levels [66] . The interaction of malnutrition and inflammation has been tested in cohort studies, as to their prognostic value for predicting mortality in prevalent dialysis patients [67] [68] [69] . In one such study, a Malnutrition-Inflammation score was shown to independently predict 5-year mortality in a prevalent hemodialyzed patient population [68] .
In dialysis patients, causes of inflammation are multifactorial and include exposure of blood to dialyzer membranes and dialysate bacterial contaminants [4] . Based on the findings of our meta-analysis, ultrapure dialysate offers the promise of decreasing markers of inflammation and oxidative stress while improving nutritional indices.
Erythropoietin hyporesponsiveness is often associated with protein-energy wasting and inflammation [70] and has been linked to an increased mortality risk [71] . In 2011, the US Food and Drug Administration informed healthcare professionals of modified recommendations for more conservative dosing of erythropoietin and darbepoetin in patients with chronic kidney disease including dialysis patients to improve the safe use of these drugs [72] . These recommendations were made because of data showing increased risks of cardiovascular events with use of erythropoietin and darbepoetin in this patient population [73, 74] . Optimizing erythropoietin-dosing regimens in dialysis patients is increasingly being scrutinized with the goal of administering the lowest dose to maintain the target hemoglobin. As a result, based on the results of our meta-analysis, the use of ultrapure dialysate in patients on long-term hemodialysis offers the promise of increasing hemoglobin level at the expense of lowering the erythropoietin dose, which would be considered cost-effective, in light of the high cost of the drug.
Strengths of our synthesis include the large sample size and the demonstrable benefit of ultrapure dialysate on several markers of inflammation, oxidative stress, serum albumin (a critical nutritional marker) and anemia parameters. Although we observed an improvement in these surrogate endpoints, the studies were of variable quality and did not examine hard clinical endpoints, thereby limiting the clinical relevance of our findings with the exception of the improvement in the anemia parameters with an increase in hemoglobin level coupled to a decrease in erythropoietin requirement. Several limitations should be emphasized. Although ultrapure dialysate is defined based on an endotoxin level of <0.03 EU/mL and a bacterial count of <0.1 CFU/mL [14] , several studies did not specify the criteria used to define ultrapure dialysate, whereas others did not employ both criterion or used different cutoff values. In our meta-analyses of single-arm cohort studies and experimental study arms, changes in the markers of interest might represent regression-to-the-mean observations. However, most of our results were replicated in metaanalyses of nonrandomized and randomized controlled studies. Our analysis was unable to account for the various assays used to measure individual markers; we did, however, explore the potential impact of dialyzer type and reuse practices on our surrogate endpoints. The mean weight was not reported in two studies [44, 51] requiring weight imputation using published data for the study country's dialysis population mean weight, which might have influenced the analysis of the weekly erythropoietin dose. The nonsignificant trend in the decrease in plasma endotoxin level following conversion to ultrapure dialysate might be due, in part, to the sample size. In our subgroup analyses, there was a nonsimilar trend of mean change in CRP and IL-6 levels, both markers of inflammation. This might be due, in part, to sample size differences and the relative instability of some of these markers in dialysis patients. Indeed, prior studies have shown that the acute-phase response is intermittent and is not a continuous feature in individual dialysis patients, with evidence of significant withinsubject coefficients of variation for acute-phase proteins such as CRP and α1-acid glycoprotein [75] . Finally, we were unable to address the cost-effectiveness associated with ultrapure dialysate.
In conclusion, conversion from conventional dialysate to ultrapure dialysate is associated with an improvement in markers of inflammation, oxidative stress and nutrition and anemia parameters. These changes might confer long-term clinical benefits, calling for the design of a large randomized controlled trial of ultrapure versus standard dialysate aimed at examining cardiovascular morbidity and mortality in dialysis patients.
